We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMhp Reg S Regulatory News (MHPC)

Share Price Information for Mhp Reg S (MHPC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 3.22
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.08 (2.484%)
Open: 3.24
High: 3.30
Low: 3.20
Prev. Close: 3.30
MHPC Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Consent Solicitation - Results Announcement

30 Mar 2022 15:55

RNS Number : 6483G
MHP SE
30 March 2022
 

THIS ANNOUNCEMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 ("MAR") AND THE RETAINED UK LAW VERSION OF MAR PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019 (SE 2019/310) ("UK MAR").

March 30, 2022

MHP SE AND MHP LUX S.A. ANNOUNCE RESULTS OF THEIR CONSENT SOLICITATION

MHP SE

(a European Public Limited Liability Company (Societas Europaea) registered in Cyprus, with registered office at 16-18 Zinas Kanther Street, Ayia Triada, 3035 Limassol, Cyprus, with Registration Number SE 27)

MHP LUX S.A.

(a public company with limited liability (société anonyme), with its registered office at 19-25 Rue des Capucins, L-1313 Luxembourg, Grand Duchy of Luxembourg, and registered with the Registre de Commerce et des Sociétés Luxembourg under number B 221.909)

 

Results of Solicitation of Consents to amend:

The indenture dated as of May 10, 2017 in relation to theU.S.$500,000,000 7.75% Guaranteed Notes due 2024 issued by MHP SE Regulation S Notes: Common Code 157796500/ ISIN XS1577965004Rule 144A Notes: Common Code 111731233/ ISIN US55302TAD72/ CUSIP 55302TAD7(the "2024 Notes Indenture") (the "2024 Notes")

The indenture dated as of April 3, 2018 in relation to theU.S.$550,000,000 6.95% Guaranteed Notes due 2026 issued by MHP Lux S.A. Regulation S Notes: Common Code 173469911/ ISIN XS1713469911Rule 144A Notes: Common Code 111730814/ ISIN US59318YAA64/ CUSIP 59318YAA6(the "2026 Notes Indenture") (the "2026 Notes")

The indenture dated as of September 19, 2019 in relation to theU.S.$350,000,000 6.25% Guaranteed Notes due 2029 issued by MHP Lux S.A. Regulation S Notes: Common Code 201004489/ ISIN XS2010044894Rule 144A Notes: Common Code 111730555/ ISIN US59318YAB48/ CUSIP 59318YAB4(the "2029 Notes Indenture" and, together with the 2024 Notes Indenture and the 2026 Notes Indenture, the "Indentures") (the "2029 Notes" and, together with the 2024 Notes and the 2026 Notes, the "Notes")

MHP SE (the "Company") and MHP Lux S.A. (the "Issuer") today announce the results of their consent solicitation (the "Consent Solicitation") to seek the consent of holders (the "Holders") of the outstanding Notes to certain proposed Amendments to the Indentures and the Notes.

The Consent Solicitation and the proposed Amendments were announced on March 21, 2022 and were made on the terms, and subject to the conditions, contained in the consent solicitation memorandum dated March 21, 2022 (the "Consent Solicitation Memorandum"). Capitalized terms used but not defined in this announcement have the same meaning ascribed to them in the Consent Solicitation Memorandum, available on the Consent Solicitation website: https://bonds.morrowsodali.com/mhp.

The Company and the Issuer now announce that the Requisite Consents of the Holders of all three series of the Notes to implement the Amendments were obtained and accepted before the Consent Expiration Time and, accordingly, Instructions Submitted are now irrevocable. The Consent Effective Time (as defined in the Consent Solicitation Memorandum) has occurred and the Amendments have been implemented by way of execution of the Supplemental Indentures on March 30, 2022.

The Consent Expiration Time is 5:00 p.m., New York City time on March 30, 2022 and Instructions can be submitted until that time and all Notes blocked with respect to Consent Solicitation will be unblocked as soon as practicable thereafter.

Requests for all information in relation to the Consent Solicitation should be directed to:

The Solicitation Agent

J.P. Morgan SE

 

Taunustor 1 (TaunusTurm)

60310 Frankfurt am Main

Germany

 

Attention: Liability Management

Email: em_europe_lm@jpmorgan.com

 

 

 

 

The Information and Tabulation Agent

Morrow Sodali Limited

Email: MHP@investor.morrowsodali.com

Consent Website: https://bonds.morrowsodali.com/mhp

In Stamford

333 Ludlow Street, South

Tower, 5th Floor, 06902

Tel: +1 203 609 4910

 

In London

103 Wigmore Street

W1U 1QS Tel: +44 20 4513 6933

In Hong Kong

The Hive Sheung Wan

33-35 Hillier Street, Sheung Wan Hong Kong

Tel: +852 2319 4130

 

This announcement has been prepared by the Company and the Issuer exclusively for information purposes. It does not constitute or include any advice or recommendation by the Company or the Issuer (or any other person) regarding the securities of the Company or the Issuer or as to the merits of any transaction or the making of any investment decision. It does not constitute or include any confirmation or commitment by the Company or the Issuer (or any other person) regarding the present or future value of the business of the Issuer, its securities, its affiliates or any of the Issuer's or their assets.

Neither this announcement nor the Consent Solicitation Memorandum constitutes or forms part of, and should not be construed as, an offer for sale or subscription of, or a solicitation of any offer to buy or subscribe for, any securities of the Issuer, the Company or any other entity in any jurisdiction.

 

The distribution of this announcement and the Consent Solicitation Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement or the Consent Solicitation Memorandum comes are required by the Issuer, the Company, the Solicitation Agent and the Information and Tabulation Agent to inform themselves about, and to observe, any such restrictions. This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

 

The Notes have not been registered under the U.S. Securities Act of 1933 (the "Securities Act") or the securities law of any state or jurisdiction of the United States and may not be reoffered or resold except pursuant to an applicable exemption from the registration requirements of the Securities Act. Neither the SEC nor any U.S. state securities commission has approved or disapproved of any Notes, or determined if the Consent Solicitation Memorandum is accurate or complete. Any representation to the contrary is a criminal offence.

 

The communication of the Consent Solicitation Memorandum and this announcement by the Company and any other documents or materials relating to the Consent Solicitation are not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000 (the "FSMA"). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. Such documents and/or materials are only directed at and may only be communicated to (1) persons who have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (2) high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (3) any other persons to whom these documents and/or materials may lawfully be communicated (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this communication or any of its contents. Nothing in this announcement constitutes or contemplates an offer to buy or the solicitation of an offer to sell securities in the United States or in any other jurisdiction.

 

Neither the Consent Solicitation Memorandum nor any documents or materials relating to the Consent Solicitation, including this announcement (collectively referred to as the "Consent Documents") have been submitted for the approval or are intended to be submitted for the approval of the Cyprus Securities and Exchange Commission and consequently neither the Consent Solicitation Memorandum nor any other Consent Documents will be distributed, released, published, communicated, advertised or disseminated, whether directly or indirectly, to the information distribution channels or to the public in Cyprus.

 

The communication of the Consent Solicitation Memorandum and of the Consent Documents in Cyprus may be made to and directed only at "professional clients" (as defined in (i) the Investment Services and Activities and Regulated Markets Law, No. 144 (I) of 2007, as amended and (ii) in the Investment Services and Activities and Regulated Markets Law, No. 87(I)/2017, as amended), by a duly licensed investment firm or credit institution (authorized under Directive 2013/36/EU) or a third-country firm providing investment services or performing investment activities through the establishment of a branch in Cyprus, permitted and authorised to conduct such activities in Cyprus and in accordance with the provisions of (i) the Investment Services and Activities and Regulated Markets Law, No. 144 (I) of 2007, as amended (ii) the Investment Services and Activities and Regulated Markets Law, No. 87(I)/2017, as amended from time to time; and (iii) Regulation (EU) No. 600/2014 of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Regulation (EU) No. 648/2012.

 

If a jurisdiction requires that the Consent Solicitation be made by a licensed broker or dealer and the Solicitation Agent or any of its affiliates is such a licensed broker or dealer in that jurisdiction, the Consent Solicitation shall be deemed to be made by the Solicitation Agent or such affiliates, as the case may be, on behalf of the Company in such jurisdiction where it/they is/are so licensed and the Consent Solicitation is not being made in any such jurisdiction where the Solicitation Agent or one of its affiliates are not so licensed.

 

Forward-Looking Statements

This announcement may contain "forward looking statements," as that term is defined by the U.S. federal securities laws, relating to the Company's business, financial condition and results of operations. You can find many of these statements by looking for words such as "may," "will," "expect," "anticipate," "believe," "estimate," "foresee," "intend," "plan," "continue" or the negatives of these terms or variations of them and similar words used in this announcement.

 

By their nature, forward looking statements are subject to numerous assumptions, risks and uncertainties. Accordingly, actual results may differ materially from those expressed or implied by the forward-looking statements. The Company cautions readers not to place undue reliance on the statements, which speak only as of the date of this announcement.

 

The cautionary statements set forth above should be considered in connection with any subsequent written or oral forward-looking statements that the Company or persons acting on the Company's behalf may issue. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this announcement. Such forward‑looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control in particular in relation to the War, that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward‑looking statements. Such forward‑looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward‑looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

All future written and verbal forward-looking statements attributable to the Company or any person acting on the Company's behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. New risks and uncertainties arise from time to time, and it is impossible for the Company to predict these events or how they may affect us. Readers are cautioned not to place undue reliance on the forward-looking statements. Except to the extent required by law, none of the Company, nor any of its agents, employees or advisors intends or has any duty or obligation to supplement, amend, update or revise any of the forward-looking statements contained in this announcement.

 

 

Please address any questions or concerns to :

Anastasiya Sobotyuk

Director of IR and International Communication

+386 4130 7265

a.sobotyuk@mhp.com.ua

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEALDEDSFAEFA
Date   Source Headline
11th Mar 20241:02 pmRNSEGM Results
7th Feb 202412:41 pmRNSEGM- Convening Notice
23rd Jan 20249:54 amRNSAppointment of a new ARC Chair
16th Nov 20237:13 amRNSQ3 and 9M 2023 Financial Results
25th Sep 20239:02 amRNSFinancial Statement Q2 2023
21st Sep 20237:06 amRNSDate Notification Q2 2023 Results
8th Sep 20237:00 amRNSMHP SE Invests in Saudi Arabia
19th Jun 20238:41 amRNSAGM results
18th May 20237:00 amRNSQ1 2023 Financial and Operational Results
17th May 202311:00 amRNSAGM Convening Notice
11th Apr 20239:42 amRNSMHP SE Standalone FS 2022
11th Apr 20239:27 amRNSMHP SE Standalone FS 2022
11th Apr 20238:54 amRNSMHP SE Standalone 2022
11th Apr 20237:00 amRNS2022 Integrated Annual Report
21st Mar 202311:07 amRNSDate Notification - Date Change
7th Mar 202310:24 amRNSEGM results
16th Feb 20231:54 pmRNSMHP and Tanmiah - announcement of a partnership
2nd Feb 20237:25 amRNSConvening Notice - EGM
25th Jan 20237:53 amRNSMonthly Operational Update - December 2022
17th Jan 20234:41 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 20227:00 amRNSMonthly Operational Update - November 2022
25th Nov 20228:00 amRNSMonthly Operational Update - October 2022
16th Nov 20227:00 amRNSQ3 and 9M 2022 Financial and Operational Results
25th Oct 20227:00 amRNSMonthly Operational Update - September
23rd Sep 20227:19 amRNSOperational Monthly Update - August 2022
14th Sep 20227:00 amRNSQ2 and H1 2022 Financial Results
2nd Sep 202212:40 pmRNSDate Change Notification
19th Aug 202210:20 amRNSOperational Monthly Update - July 2022
9th Aug 20224:41 pmRNSSecond Price Monitoring Extn
9th Aug 20224:36 pmRNSPrice Monitoring Extension
27th Jul 20227:13 amRNSQ2 and H1 2022 Pre close trading update
22nd Jul 20227:21 amRNSOperational Monthly Update - June 2022
30th Jun 20222:22 pmRNS2021 MHP Sustainability Report
24th Jun 20227:27 amRNSMHP Monthly Update - May 2022
17th Jun 20227:56 amRNSQ1 2022 Financial Results
24th May 20227:44 amRNSMonthly Operational Update for April 2022
17th May 202212:25 pmRNSAGM - Convening Notice
5th May 202212:06 pmRNSSeparate FS
5th May 202210:57 amRNSFinancial Results for the Q4 and 12M 2021
28th Apr 202210:16 amRNSDate notification
22nd Apr 20229:43 amRNSPre-Close TU for the Q1 2022
11th Apr 202210:48 amRNSMHP - Operational Update
30th Mar 20223:55 pmRNSConsent Solicitation - Results Announcement
23rd Mar 20221:40 pmRNSUpdate Announcement - Consent Solicitation
21st Mar 202210:49 amRNSMHP - Consent Solicitation Announcement
18th Mar 20221:57 pmRNSCoupon Payment Information
14th Mar 20229:41 amRNSDamage to Warehouse - Loss of Produce
10th Mar 20228:26 amRNSMHP - SUPPORT FOR UKRAINE
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.